Table 5 R50% and R75% responder rates from galcanezumab RCTs and real-world studies
Study | 3-months R50% | 3-months R75% | 6-months R50% | 6-months R75% |
|---|---|---|---|---|
EVOLVE-1 [1] (n = 425) | 62.3% (120mg), 60.9% (240mg) | 38.8% (120mg), 38.5% (240mg) | ||
EVOLVE-2 [2] (n = 454) | 59.3% (120mg), 56.5% (240 mg) | 33.5% (120mg), 34.3% (240mg) | ||
REGAIN [4] (n = 529) | 27.6% (120mg), 27.5% (240mg) | 7.0% (120mg), 8.8% (240mg) | ||
CONQUER [6] (n = 232) | 41.8% (EM), 32.0% (CM) | 18.4% (EM), 8.8% (CM) | ||
PERSIST [21] (n = 260) | 54.9% | 29.2% | ||
PERSIST [22] open label (n = 484) | 69.0% | 46.7% | ||
Takizawa et al. [9] (n = 52) | 62% (all), 76% (EM), 48% (CM) | 35% (all), 40% EM, 30% (CM) | ||
Vernieri et al. [10] (n = 245) | 79.4% (EM), 93.8% (CM) | 44.1% (EM), 40.6% (CM) | ||
Kim et al. [23] (n = 104) | 55.7% | |||
GALCA-ONLY (n = 1055) | 49.8% (all), 61.8% (EM), 46% (CM) | 24.2% (all), 31.7% (EM), 21.8% (CM) | 48.8% (all), 58.2% (EM), 45.9% (CM) | 24.6% (all), 27.3% (EM), 21.3% (CM) |